FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12

FRIDAY, June 21, 2019 -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news